Top 10 Traditional Chinese Medicine Brands

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a leading Chinese multinational pharmaceutical and health products conglomerate headquartered in Guangzhou, Guangdong Province. With total annual revenue of CNY 77.66 billion (~USD 10.8 billion) in 2025, it ranks as the largest enterprise in the global Traditional Chinese Medicine (TCM) and wellness sector. The group operates across the entire pharmaceutical value chain, from raw material cultivation and modern extraction to consumer health products and international trade, with flagship brands including Baiyunshan and Chenliji (founded in the Ming Dynasty).

Strengths: (1) Unparalleled scale with CNY 77.66 billion in annual revenue, the highest in the global TCM sector; (2) Diversified portfolio spanning chemical pharmaceuticals, traditional Chinese medicines, and health consumer goods; (3) Ownership of time-honored brands such as Chenliji and Caizhilin with heritage dating back to the Ming Dynasty; (4) Full supply chain integration from medicinal herb cultivation to high-speed automated packaging; (5) Strong dividend policy with a 46.32% payout ratio in 2025, maintaining investor confidence.

Weaknesses: (1) High dependency on domestic China market limits international revenue diversification; (2) Complex multi-subsidiary structure creates operational complexity and brand dilution risk; (3) Exposure to fluctuating raw material costs for key ingredients such as rare medicinal herbs.

Yunnan Baiyao Group Co., Ltd. is one of China's most iconic pharmaceutical companies, renowned for its flagship Yunnan Baiyao hemostatic powder originally created in 1902. Headquartered in Kunming, Yunnan Province, the group achieved CNY 41.19 billion in annual revenue in 2025 with net profit of CNY 5.15 billion (up 8.51% YoY). The group has masterfully expanded from traditional hemostatic applications into cross-category consumer products including oral care (Yunnan Baiyao toothpaste), personal care, and functional wellness beverages, generating over CNY 2.5 billion from its core aerosol spray product line alone.

Strengths: (1) 120+ years of brand heritage with irreplaceable consumer trust in hemostasis and wound healing; (2) Exceptional single-product conversion rates - the Yunnan Baiyao aerosol spray exceeded CNY 2.5 billion in 2025 sales; (3) Successful brand extension into high-margin consumer categories such as toothpaste and skincare; (4) Strong R&D investment of CNY 423 million in 2025 (+21.51% YoY), focusing on nuclear medicine as a second growth curve; (5) Strategic exit from secondary market securities trading in 2025 to refocus on core pharma operations.

Weaknesses: (1) High reliance on a limited number of core products creates concentration risk; (2) International market penetration remains minimal compared to domestic scale; (3) Increasing raw material costs for rare herbs pressure margins.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu) is a state-controlled OTC pharmaceutical giant and the undisputed leader in China's cold, cough, and digestive tract TCM segments. Listed on the Shenzhen Stock Exchange (000999.SZ) and headquartered in Shenzhen, the company generated CNY 27.61 billion in annual revenue in 2025, with net profit surging 18.05% to CNY 3.367 billion and an industry-leading gross margin of 53.91%. The group operates the iconic 999 (Sanjiu) brand and was designated as an Excellence-level Smart Factory by China's MIIT in 2025, with 15 manufacturing subsidiaries certified to ISO 14001 environmental standards.

Strengths: (1) Dominant market share in OTC cold/cough TCM with near-household-name brand recognition; (2) Best-in-class profitability with 53.91% gross margin and 18.05% net profit growth; (3) Strategic acquisition of Tasly Pharmaceutical completed in 2025, creating a TCM industry super-tanker; (4) Advanced intelligent manufacturing infrastructure recognized by MIIT as Excellence-level Smart Factory; (5) Robust ESG credentials with 600+ EHS drills and ISO 14001 certification across 15 manufacturing subsidiaries.

Weaknesses: (1) Post-acquisition integration risks with Tasly create operational complexity; (2) Heavy B2B hospital channel exposure subject to centralized procurement (VBP) policy risks; (3) Limited brand diversity beyond the 999 family, creating single-brand concentration.

Tsumura & Co. is the world's most technologically advanced and quality-compliant manufacturer of Kampo (Japanese traditional medicine) products, listed on the Tokyo Stock Exchange (4540.T). Headquartered in Tokyo, Tsumura achieved JPY 198 billion (~CNY 9.5 billion) in net sales for fiscal year 2025/2026, representing 9.3% growth. The company commands an overwhelming 83%+ market share in Japan's prescribed Kampo formulations, with 8.5% of the total Japanese pharmaceutical market. Its four manufacturing plants (in Shizuoka, Ibaraki, Shanghai, and Tianjin) and a proprietary 1,000-hectare medicinal herb farm in Yubari, Hokkaido produce over 2,000 tons of certified raw materials annually under full barcode-level traceability systems.

Strengths: (1) Gold-standard quality compliance - the only TCM manufacturer meeting Japanese Pharma GMP and FDA-level standards; (2) Vertical integration from farmland (1,000-hectare Hokkaido farm) to automated extraction plants enables unmatched traceability; (3) 83%+ monopoly in Japan's prescribed Kampo market creates near-inexhaustible pricing power; (4) Four global manufacturing bases allow flexible, small-batch multi-product production; (5) Strong R&D investment in Evidence-Based Kampo medicine generates high barriers to entry.

Weaknesses: (1) Revenue scale significantly smaller than Chinese TCM giants (only JPY 198B vs CNY 77.6B for Baiyunshan); (2) High raw material (rough medicinal herb) procurement costs squeeze margins amid global supply constraints; (3) Limited product portfolio beyond prescription Kampo restricts consumer market expansion.

Beijing Tong Ren Tang Co., Ltd. is China's oldest and most culturally significant pharmaceutical brand, founded in 1669 during the Qing Dynasty under the reign of Emperor Kangxi. Listed on the Shanghai Stock Exchange (600085.SH) and Hong Kong Exchange (3613.HK), the group generated CNY 17.26 billion in revenue in 2025, a decline of 7.2% year-on-year amid challenging macroeconomic conditions and surging raw material costs. Despite short-term financial headwinds, Tong Ren Tang retains unparalleled brand prestige globally, particularly in emergency cardiovascular care, sedative/anxiolytic treatments, and premium tonic preparations such as An Gong Niu Huang Wan and Tong Ren Niuhuang Qingxin Wan. The group's international retail network spans dozens of countries through its Hong Kong-listed platform and direct-operation TCM clinics.

Strengths: (1) Unmatched 355-year brand heritage creating irreplaceable consumer trust in premium TCM; (2) Exclusive pricing power in high-margin emergency and neurological preparations; (3) Global distribution network covering Southeast Asia, North America, and Europe serving overseas Chinese communities; (4) Strong diversification into national trend health beverages and AI-powered digital retail transformation; (5) Premium market positioning insulated from centralized procurement (VBP) pressure through private retail channels.

Weaknesses: (1) Severe Q4 2025 profit decline of 93.3% due to rare medicinal herb cost volatility; (2) Revenue contraction of 7.2% reflects structural challenges in legacy product portfolios; (3) Heavy dependency on traditional high-margin products creates risk if consumer preferences shift.

China Traditional Chinese Medicine Holdings Co. Limited (China TCM) is the largest manufacturer of TCM concentrated granule formulations and medicinal herb slices in the world, operating as a core platform under Sinopharm Group. Listed on the Hong Kong Stock Exchange (0570.HK) and headquartered in Foshan, Guangdong, the company posted CNY 14.74 billion in revenue in 2025, a 10.7% decline caused by the inclusion of TCM formula granules in China's national Volume-Based Procurement (VBP) scheme. Despite financial headwinds, China TCM operates the world's most extensive raw material sourcing network: 162 certified production bases across 22 provinces covering over 30,600 hectares of medicinal herb cultivation, with 95 of its 109 core herb varieties achieving full blockchain-level quality traceability as of 2025.

Strengths: (1) Largest TCM formula granule manufacturing scale globally with dominant market pricing influence; (2) 162 raw material production bases covering 22 Chinese provinces - a near-impossible replication barrier; (3) 95 of 109 core herbs achieve full online quality traceability, setting the national standard; (4) Sinopharm Group backing provides unparalleled hospital channel access and supply chain financing; (5) Deleveraging success: debt-to-asset ratio improved from 31.74% to 28.81% in 2025 despite industry contraction.

Weaknesses: (1) Revenue decline of 10.7% and net loss of CNY 458 million due to VBP price cuts; (2) High government policy dependency - VBP inclusion creates permanent pricing pressure; (3) Dominant B2B hospital channel limits consumer retail market flexibility.

Health and Happiness (H&H) International Holdings Limited is a multinational nutrition and wellness group dual-headquartered in Hong Kong and Melbourne, Australia. The company achieved CNY 14.30 billion (~USD 2.28 billion) in revenue in 2025 with a strong 10.3% year-on-year increase and net profit growth of 22.7%. Its crown jewel, the Swisse adult nutrition brand, surpassed USD 1 billion in global annual revenue in 2025 - exactly a decade after H&H acquired the Australian icon. The group operates a new 17,000 sqm National Operations Centre in Ravenhall, Victoria, with three fully automated production lines capable of producing 7 million bottles of supplements per year, and has achieved B Corp certification for environmental and social responsibility standards.

Strengths: (1) Swisse brand exceeding USD 1 billion in revenue establishes a rare global wellness milestone for a Chinese-controlled brand; (2) Tri-continental market presence across Asia, Australia, and Europe with 15+ country exports; (3) Best-in-class manufacturing: new Australian facility with 433kW solar array and rainwater recycling supports B Corp certification; (4) Successful cross-border brand M&A integration - the gold standard case study for Chinese overseas acquisition; (5) Strong growth with net profit up 22.7% and 10.3% revenue growth outpacing the broader VDS market.

Weaknesses: (1) High exposure to Australia's regulatory environment and TGA compliance costs; (2) Revenue concentration in ANC (adult nutrition care) brand Swisse creates single-brand risk; (3) Macro consumer spending pressure in China and Australia could impact premium pricing power.

Tasly Pharmaceutical Group Co., Ltd. is a leading Chinese innovative TCM company specializing in cardiovascular and cerebrovascular prescription drugs, headquartered in Tianjin. Listed on the Shanghai Stock Exchange (600535.SH), the group recorded CNY 8.236 billion in total revenue in 2025 with CNY 1.104 billion in net profit, and a robust gross margin of 66.76%. The company's signature products and core cardiac drug pipeline position Tasly at the intersection of evidence-based TCM and FDA-compliant modern pharmaceuticals. In 2025, China Resources Sanjiu (CR Sanjiu) completed its strategic acquisition of Tasly, creating a TCM super-tanker with combined revenue exceeding CNY 35 billion. Tasly maintains a robust R&D pipeline of 98 products under development with multi-billion RMB R&D investment.

Strengths: (1) High-margin product structure with 66.76% gross margin reflecting premium pricing power in cardiovascular TCM; (2) FDA-cGMP compliant manufacturing facilities enabling potential international market entry; (3) 98-product R&D pipeline with multi-billion RMB R&D investment creates long-term competitive moat; (4) Strategic acquisition by CR Sanjiu in 2025 provides access to state-owned enterprise distribution network and policy resources; (5) Established international patents on core extraction and micro-particle formulation technologies.

Weaknesses: (1) Acquisition by CR Sanjiu in 2025 creates brand independence concerns and integration execution risk; (2) Heavy concentration in hospital prescription channel exposes the group to ongoing VBP pricing pressure; (3) International revenue remains negligible, limiting global scale diversification.

By-health Co., Ltd. is China's pioneer and market leader in the vitamin and dietary supplement (VDS) non-direct-sales channel, listed on the Shenzhen Stock Exchange (300146.SZ) and headquartered in Zhuhai, Guangdong. The company generated approximately CNY 6.27 billion in annual revenue in 2025, facing macro consumer weakness and channel migration to live-stream e-commerce. Its 40,000 sqm Transparent Factory 3.0 in Zhuhai - built at a cost of CNY 420 million - features over 200 sets of globally sourced automated equipment, China's first pneumatic rail logistics system, and annual production capacity of 5 billion tablets, 3 billion softgels, and 500 million hard capsules. By-health was the first Chinese company to open its manufacturing facility to public supervision, having received over 2 million visitors since inception.

Strengths: (1) Industry-leading transparent factory with full public audit access builds unparalleled consumer trust and quality credibility; (2) Massive production scale of 5 billion tablets and 3 billion softgels - the largest non-direct-sales VDS manufacturing capacity in China; (3) Global ingredient sourcing model featuring 20+ countries with full supply chain transparency; (4) Pioneering AI-powered Multi-Dimensional Homeostasis Health Evaluation System in development for next-generation personalized nutrition; (5) First Chinese VDS company to adopt comprehensive third-party manufacturing transparency standards.

Weaknesses: (1) Revenue decline of 8.4-20% reflects intense competitive pressure from live-stream e-commerce channels; (2) Net profit down 17.34% in H1 2025 amid macro consumer spending headwinds; (3) Heavy investment in Transparent Factory 3.0 creates fixed cost burden during revenue contraction.

Korea Ginseng Corporation (KT&G) is the world's dominant red ginseng and premium tonic health products company, headquartered in Seoul and Daejeon, South Korea. As a wholly-owned subsidiary of KT&G (Korea Tobacco and Ginseng), listed on the Korea Exchange (033780.KS), the corporation generated KRW 1.137 trillion (~CNY 6.0 billion) in health functional food revenue in 2025. Its flagship Cheong Kwan Jang (JUNG KWAN JANG) brand commands approximately 80% market share in South Korea's domestic red ginseng market and has expanded to 40+ countries globally. The group operates a fully vertically integrated supply chain from 6-year cultivated ginseng farming through concentrated liquid extraction to retail-ready premium products, including the iconic Red Ginseng Everytime (30-pack) and G1899 B2B standardized raw material brand.

Strengths: (1) ~80% domestic market monopoly in red ginseng creates near-inexhaustible pricing power and brand loyalty; (2) 100% vertical integration from soil monitoring and 6-year ginseng cultivation to automated extraction and packaging; (3) Global expansion with presence in 40+ countries and strong duty-free channel partnerships; (4) Premium brand repositioning strategy - successful 4.9% price increase on flagship Red Ginseng Everytime to maintain luxury positioning; (5) New B2B raw material brand G1899 creates second revenue growth curve beyond retail.

Weaknesses: (1) Revenue decline of 12.6% in health functional foods reflects structural shift among younger Korean consumers toward probiotics and multivitamins; (2) High dependency on Korean domestic market limits global scale; (3) Declining youth engagement with traditional heavy ginseng formats requires ongoing brand modernization investment.